Traduction de «disease than » (Néerlandais → Français) :

TERMINOLOGIE

central-core-disease | congenitale spierdystrofie | NNO | congenitale spierdystrofie | met specifieke morfologische-afwijkingen van spiervezel | fibre-type disproportion | minicore disease | multicore disease | myopathie | myotubulair (centronucleair) | myopathie | nemaline lichaampjes
Disproportion des types de fibres Dystrophie musculaire congénitale:SAI | avec anomalies morphologiques spécifiques des fibres musculaires | Myopathie:à axe central | à bâtonnets [némaline] | de type: mini-core | multi-core | myotubulaire (centro-nucléaire)

genezen myocardinfarct | vroeger myocardinfarct, gediagnosticeerd door ECG of ander speciaal onderzoek, maar thans zonder symptomen
Infarctus du myocarde:ancien découvert par ECG ou autre moyen d'investigation, mais asymptomatique au moment de l'examen | guéri

ziekte van Franklin | gamma heavy chain disease | Mmu heavy chain disease
Maladie de Franklin

ADTKD-UMOD - UMOD-related autosomal dominant tubulointerstitial kidney disease
néphropathie tubulo-interstitielle autosomique dominante associée à UMOD

Border disease-virus
virus Border disease

Borna disease-virus
virus Borna disease

ADPCLD - autosomal dominant polycystic liver disease
polykystose hépatique isolée

AIED - Åland Islands eye disease
maladie ophtalmique des îles Åland

ADTKD-MUC1 - MUC1-related autosomal dominant tubulointerstitial kidney disease
néphropathie tubulo-intersitielle autosomique dominante associée à MUC1

bovien mucosal disease-virus
virus Bovine mucosal disease

TRADUCTIONS EN CONTEXTE

Exelon/Exelon Patch (USD 954 million, +22% lc), a therapy for mild to moderate forms of Alzheimer’s disease dementia as well as dementia linked with Parkinson’s disease, achieved more than half of its sales from Exelon Patch, the novel skin patch launched in late 2007 that is now available in more than 60 countries worldwide.
Exelon/Exelon Patch (USD 954 millions, +22% en m. l) est un traitement des formes légères à modérées de la maladie d'Alzheimer et de la démence associée à la maladie de Parkinson. Plus de la moitié des ventes est réalisée par Exelon Patch, une nouvelle formulation de patch transdermique lancée fin 2007 et désormais disponible dans plus de 60 pays.

Exelon Patch is approved for the treatment of mild to moderate Alzheimer’s disease dementia in more than 75 countries, including more than 20 countries where it is also approved for dementia associated with Parkinson’s disease.
Exelon Patch est autorisé dans plus de 75 pays pour le traitement des formes légère à modérée de la maladie d'Alzheimer et dans plus de 20 pour celui de la démence associée à la maladie de Parkinson.

Exelon Patch is approved for the treatment of mild-to-moderate Alzheimer’s disease dementia in more than 75 countries, including more than 20 countries where it is also approved for dementia associated with Parkinson’s disease.
Exelon Patch est autorisé dans plus de 75 pays pour le traitement des formes légère à modérée de la maladie d'Alzheimer et dans plus de vingt pour celui de la démence associée à la maladie de Parkinson.

Exelon/Exelon Patch (USD 687 million, +24 % lc), a therapy for mild to moderate forms of Alzheimer’s disease dementia as well as dementia linked with Parkinson’s disease, now achieves more than half of its sales from Exelon Patch, the novel skin patch launched in late 2007 and now available in more than 50 countries worldwide.
Exelon/Exelon Patch (USD 687 millions, +24% en m. l.), traitement des formes légères à modérées de la maladie d'Alzheimer et de la démence associée à la maladie de Parkinson, a bénéficié du lancement à fin 2007 d’Exelon Patch, une nouvelle formulation de patch transdermique, qui est désormais disponible dans plus de 50 pays.

This biotechnology eye therapy, which is approved in more than 80 countries for “wet” age-related macular degeneration, has now been used in more than 250,000 patients for this disease, a leading cause of blindness in people over age 50.
Ce traitement oculaire issu des biotechnologies, autorisé dans plus de 80 pays contre la forme exsudative de la dégénérescence maculaire liée à l'âge, cause principale de cécité chez les personnes âgées de plus de 50 ans, a été utilisé chez plus de 250 000 malades.

Cushing's disease is a debilitating hormonal disorder for which there are currently no approved medicines. In another Phase III study, Onbrez Breezhaler was shown to be significantly better in the treatment of chronic obstructive pulmonary disease (COPD) than salmeterol, one of the current mainstays of treatment.
Dans une autre étude de phase III, Onbrez Breezhaler s’est montré bien meilleur pour traiter la broncho-pneumopathie chronique obstructive (BPCO) que salmétérol, l’un des principaux traitements courants.

Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease
Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease perioperative risks ii . NICE Minor surgery: ASA I : not indicated ASA II : consider > 40 y if respiratory or CV disease ASA III : consider if respiratory or CV disease Intermediate surgery: ASA I : not indicated ASA II : consider if respiratory or CV disease (renal > 60y) ASA III : consider if respiratory, CV or renal disease Major surgery: ASA I : consider > 60 ASA II : consider if respiratory, CV or renal disease ASA III : consider if respiratory, CV or renal disease

Approved in up to six indications worldwide, Reclast/Aclasta provides fracture protection to a broad spectrum of patients ranging from those diagnosed with early bone loss to patients with more severe forms of the disease and has been used in more than one million infusions.
Autorisé pour jusqu’à six indications dans le monde entier, Aclasta/Reclast protège contre les fractures sur toute l’étendue de la maladie allant de la perte osseuse précoce aux formes plus sévères.